Liquidia Co. (NASDAQ:LQDA) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Liquidia Co. (NASDAQ:LQDA - Free Report) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,557,296 shares of the company's stock after purchasing an additional 115,367 shares during the quarter. Vanguard Group Inc. owned about 4.20% of Liquidia worth $41,834,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in Liquidia by 9.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock valued at $5,040,000 after acquiring an additional 38,313 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Liquidia by 855.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after purchasing an additional 210,753 shares during the period. Bank of New York Mellon Corp increased its position in shares of Liquidia by 3.3% during the 4th quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company's stock worth $2,218,000 after purchasing an additional 6,034 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Liquidia by 12.5% during the 3rd quarter. Wellington Management Group LLP now owns 179,923 shares of the company's stock worth $1,799,000 after purchasing an additional 19,932 shares during the last quarter. Finally, Swiss National Bank raised its holdings in Liquidia by 20.6% in the 4th quarter. Swiss National Bank now owns 107,900 shares of the company's stock valued at $1,269,000 after buying an additional 18,400 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Liquidia Stock Performance

LQDA stock traded down $0.23 during mid-day trading on Tuesday, reaching $13.60. The company had a trading volume of 697,219 shares, compared to its average volume of 965,941. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -8.34 and a beta of 0.23. The firm has a fifty day simple moving average of $14.84 and a 200 day simple moving average of $12.72.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. As a group, analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of Liquidia stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares of the company's stock, valued at $3,483,259. The trade was a 0.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 30.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LQDA. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They set an "overweight" rating and a $20.00 price target for the company. Scotiabank reissued an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Needham & Company LLC restated a "buy" rating and set a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $26.63.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).